Most notably, unlike the prior work by Colditz et al. detailing a relationship between BRAF mutational status predicting favorable outcomes in melanoma patients [41], we were not able to find significant associations between mutational status and EOR as well as OS in our lung cancer cohort. The gene discussed is BRAF; the disease is lung cancer.